Literature DB >> 29458448

Rubella antibodies in cord blood sera in Portugal: association with maternal age and vaccination status.

J Frade1,2, C Nunes3, J R Mesquita4, M São José Nascimento5, G Gonçalves1.   

Abstract

This study evaluated the impact of maternal vaccination against rubella on the levels of specific rubella IgG (rIgG) in 198 newborn cord sera samples. Detailed maternal vaccination data were available. Specific rIgG was measured using a commercial enzyme immunoassay. Most mothers (78.8%) had been vaccinated against rubella at least once in their lives. In 15 (7.6%) cord sera samples, the concentration of specific rIgG was below 11 IU/ml, which was classified as seronegative. Statistical analysis using multiple logistic regression (n = 198) showed that newborns of mothers born between 1986 and 1995, and those born to unvaccinated mothers, were more likely to be seronegative (odds ratio (ORs) 5.2 and 4.9, respectively, adjusted for sex and gestational age). For vaccinated mothers (n = 156), those born between 1986 and 1995 were more likely to have seronegative newborns (OR 11.5 adjusting for sex, gestational age and time since last vaccination). Mothers of the 15 (7.6%) seronegative newborns might have been susceptible to rubella during pregnancy. Checking the vaccination status therefore recommended.

Entities:  

Keywords:  Immunisation (vaccination); MMR vaccination; rubella; serology

Mesh:

Substances:

Year:  2018        PMID: 29458448      PMCID: PMC9134545          DOI: 10.1017/S0950268818000237

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  12 in total

1.  Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns.

Authors:  Birgit Leineweber; Veit Grote; Urs B Schaad; Ulrich Heininger
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

2.  Measles antibodies in cord blood in Portugal: Possible consequences for the recommended age of vaccination.

Authors:  Guilherme Gonçalves; Carla Nunes; João Rodrigo Mesquita; Maria São José Nascimento; João Frade
Journal:  Vaccine       Date:  2016-04-22       Impact factor: 3.641

3.  Levels of rubella antibody among vaccinated and unvaccinated Portuguese mothers and their newborns.

Authors:  Guilherme Gonçalves; Maria São José Nascimento; Cristina Réu; Felicity T Cutts
Journal:  Vaccine       Date:  2006-07-12       Impact factor: 3.641

Review 4.  Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella.

Authors:  S E Robertson; F T Cutts; R Samuel; J L Diaz-Ortega
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

5.  Placental transfer of rubella-specific IgG in fullterm and preterm newborns.

Authors:  M Doroudchi; A Samsami Dehaghani; K Emad; A Ghaderi
Journal:  Int J Gynaecol Obstet       Date:  2003-05       Impact factor: 3.561

6.  Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization.

Authors:  H Sato; P Albrecht; D W Reynolds; S Stagno; F A Ennis
Journal:  Am J Dis Child       Date:  1979-12

7.  Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Lukas Matter; Susan E Reef; Carol Beck; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

Review 8.  Measles elimination: progress, challenges and implications for rubella control.

Authors:  Felicity T Cutts; Justin Lessler; Charlotte J E Metcalf
Journal:  Expert Rev Vaccines       Date:  2013-08       Impact factor: 5.217

Review 9.  [Congenital rubella. Still with us].

Authors:  M J Saldanha; A Azevedo
Journal:  Acta Med Port       Date:  1995-05

10.  Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal.

Authors:  G Gonçalves; J Frade; M S J Nascimento; J R Mesquita; C Nunes
Journal:  Epidemiol Infect       Date:  2016-08-04       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.